Stryker shares fell 6.42% following its second quarter 2026 earnings release, which reported sales of US$6.59 billion and net income of US$1.28 billion. The decline pulled the year-to-date return down 6.46%, though the five-year total shareholder return remains at 30.66%. After the drop, Stryker is trading at a discount of about 23% to one valuation estimate and roughly 18% below the average analyst target, with the most followed narrative placing fair value at $386.80 versus the last close of $325.70. Analyst price targets range from a bullish $465.00 to a bearish $315.00, with a consensus of $386.80. The narrative highlights compounding revenue, rising margins, and a richer earnings multiple, but notes risks from prolonged EU regulatory delays or sustained supply chain disruptions.
Stryker CorporationQ2 earnings release with sales and net income, causing shares to drop 6.42%